|1.||Schoenlein, Patricia V: 3 articles (04/2009 - 08/2004)|
|2.||Barrett, John T: 3 articles (04/2009 - 08/2004)|
|3.||Sánchez, Jose A: 2 articles (05/2013 - 12/2011)|
|4.||Fernández-Sanz, Celia: 2 articles (05/2013 - 12/2011)|
|5.||Rodríguez-Sinovas, Antonio: 2 articles (05/2013 - 12/2011)|
|6.||Ruiz-Meana, Marisol: 2 articles (05/2013 - 12/2011)|
|7.||García-Dorado, David: 2 articles (05/2013 - 12/2011)|
|8.||Samaddar, Julia S: 2 articles (04/2009 - 09/2008)|
|9.||Gaddy, Virgil T: 2 articles (09/2008 - 08/2004)|
|10.||Fornander, Tommy: 1 article (10/2015)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2013 - "Low doses of 4-OHT induced proliferation of these breast cancer cell lines. "
03/01/2011 - "Furthermore, their antiproliferative activity against MCF-7 human breast cancer cell line is comparable to that of TAM, RAL and 4-OHT."
06/01/2010 - "These results suggest that downregulation of ENO-1 could be utilized as a novel pharmacological approach for overcoming 4-OHT resistance in breast cancer therapy."
03/15/2005 - "Although the effects of 4-OHT are observed at micromolar concentrations, cellular mechanisms responsible for G(1) arrest, as well as apoptosis induction, are similar to those observed in breast cancer cells. "
01/01/2010 - "These data confirm that SULT1A1-mediated biotransformation of 4-OHT is important in the efficacy of 4-OHT cytotoxicity in breast tumors, and reveals a potential role for sulfated metabolites in the efficacy of tamoxifen therapy."
01/01/2015 - "These data demonstrate critical differences in cellular energetics and responses to 4-OHT in these two ERα+ cell lines, likely reflecting cancer cell avoidance of apoptosis. "
06/01/2010 - "These data imply that changes in tumor ENO-1 levels are related to clinical 4-OHT therapeutic outcome. "
06/15/2005 - "Subsequent inactivation of MycER via 4-OHT deprivation resulted in tumor stasis but only partial regression. "
05/01/2005 - "Percutaneous 4-OHT gel has a local impact on tumor proliferation. "
10/01/2015 - "Three different breast epithelia cancer cell lines were exposed to E2 and 4-OHT and mRNA expression was analyzed using qPCR. "
05/01/2013 - "Isolated hearts from Cx43(Cre-ER(T)/fl) mice, or from Cx43(fl/fl) controls, treated with vehicle or 4-OHT, were submitted to global ischemia (40 min) and reperfusion. "
12/01/2011 - "In conclusion, both reduction of Cx43 with 4-OHT and replacement of Cx43 by less-conductive Cx32 were arrhythmogenic under normoxia and ischemia-reperfusion, despite no major effects on baseline electrical properties. "
|5.||Endometrial Neoplasms (Endometrial Cancer)
|2.||Estrogen Receptor Modulators (Antiestrogen)
|3.||Small Interfering RNA (siRNA)
|4.||benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
|6.||Connexin 43 (Connexin43)
|7.||Estrogen Receptor alpha
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Ethylene Glycol (Monoethylene Glycol)
|10.||Proliferating Cell Nuclear Antigen (PCNA)